Trials / Unknown
UnknownNCT03511859
Detecting Circulating Tumor Cells (CTCs) and Cell Free DNA (cfDNA) in Peripheral Blood of Breast Cancer (BC) Patients to Develop the Clinical Application for Early Detection and Diagnostics
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 210 (estimated)
- Sponsor
- CellMaxLife · Industry
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Accepted
Summary
Utilization of circulating-tumor-cell (CTC) and cell free DNA (cfDNA) as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In the wake of FDA approval of a liquid biopsy test, it is important for clinicians to acknowledge the obvious clinical utility of liquid biopsy for cancer management throughout the course of the disease.
Conditions
Timeline
- Start date
- 2017-11-16
- Primary completion
- 2018-12-31
- Completion
- 2019-12-31
- First posted
- 2018-04-30
- Last updated
- 2018-04-30
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03511859. Inclusion in this directory is not an endorsement.